Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gunnar Brobert

Showing results (11-20 of 35) with videos related to

Pageof 4
Sort By:
Clinical Epidemiology|November 9, 2022
Acute Kidney Injury in Patients with Non-Valvular Atrial Fibrillation Treated with Rivaroxaban or Warfarin: A Population-Based Study from the United KingdomAntonio González-Pérez, Yanina Balabanova, María E Sáez, et al.
International Journal of Cardiology|February 5, 2022
Renal decline in patients with non-valvular atrial fibrillation treated with rivaroxaban or warfarin: A population-based study from the United KingdomAntonio González Pérez, Yanina Balabanova, María E Sáez, et al.
World Journal of Gastroenterology|June 6, 2022
Risk factors for major gastrointestinal bleeding in the general population in FinlandPareen Vora, Ronald Herrera, Arto Pietila, et al.
Plos One|February 22, 2020
Overall survival and second primary malignancies in men with metastatic prostate cancerJuha Mehtälä, Jihong Zong, Zdravko Vassilev, et al.
Pharmacoepidemiology and Drug Safety|August 22, 2022
Pre- and post-stroke oral antithrombotics and mortality in patients with ischaemic strokeLuis A García Rodríguez, David Gaist, Yanina Balabanova, et al.
BMJ Open|October 21, 2019
Discontinuation of non-Vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation: a population-based cohort study using primary care data from The Health Improvement Network in the UKAna Ruigómez, Pareen Vora, Yanina Balabanova, et al.
BMJ Open|June 2, 2022
Safety and effectiveness of appropriately and inappropriately dosed rivaroxaban or apixaban versus warfarin in patients with atrial fibrillation: a cohort study with nested case-control analyses from UK primary careAntonio González-Pérez, Luke Roberts, Pareen Vora, et al.
Human Psychopharmacology|June 15, 2016
Post authorization safety study comparing quetiapine to risperidone and olanzapineEdith M Heintjes, Jetty A Overbeek, Fernie J A Penning-van Beest, et al.
Heart (British Cardiac Society)|December 14, 2020
Discontinuation of oral anticoagulation in atrial fibrillation and risk of ischaemic strokeLuis Alberto García Rodríguez, Lucía Cea Soriano, Stine Munk Hald, et al.
Drugs - Real World Outcomes|February 1, 2023
Time Trends in Patient Characteristics of New Rivaroxaban Users with Atrial Fibrillation in Germany and the NetherlandsAnnemarie Voss, Elisabeth Smits, Karin M A Swart, et al.
Pageof 4

Showing results (11-20 of 35) with videos related to

Sort By:
Pageof 4
Clinical Epidemiology|November 9, 2022
Acute Kidney Injury in Patients with Non-Valvular Atrial Fibrillation Treated with Rivaroxaban or Warfarin: A Population-Based Study from the United KingdomAntonio González-Pérez, Yanina Balabanova, María E Sáez, et al.
International Journal of Cardiology|February 5, 2022
Renal decline in patients with non-valvular atrial fibrillation treated with rivaroxaban or warfarin: A population-based study from the United KingdomAntonio González Pérez, Yanina Balabanova, María E Sáez, et al.
World Journal of Gastroenterology|June 6, 2022
Risk factors for major gastrointestinal bleeding in the general population in FinlandPareen Vora, Ronald Herrera, Arto Pietila, et al.
Plos One|February 22, 2020
Overall survival and second primary malignancies in men with metastatic prostate cancerJuha Mehtälä, Jihong Zong, Zdravko Vassilev, et al.
Pharmacoepidemiology and Drug Safety|August 22, 2022
Pre- and post-stroke oral antithrombotics and mortality in patients with ischaemic strokeLuis A García Rodríguez, David Gaist, Yanina Balabanova, et al.
BMJ Open|October 21, 2019
Discontinuation of non-Vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation: a population-based cohort study using primary care data from The Health Improvement Network in the UKAna Ruigómez, Pareen Vora, Yanina Balabanova, et al.
BMJ Open|June 2, 2022
Safety and effectiveness of appropriately and inappropriately dosed rivaroxaban or apixaban versus warfarin in patients with atrial fibrillation: a cohort study with nested case-control analyses from UK primary careAntonio González-Pérez, Luke Roberts, Pareen Vora, et al.
Human Psychopharmacology|June 15, 2016
Post authorization safety study comparing quetiapine to risperidone and olanzapineEdith M Heintjes, Jetty A Overbeek, Fernie J A Penning-van Beest, et al.
Heart (British Cardiac Society)|December 14, 2020
Discontinuation of oral anticoagulation in atrial fibrillation and risk of ischaemic strokeLuis Alberto García Rodríguez, Lucía Cea Soriano, Stine Munk Hald, et al.
Drugs - Real World Outcomes|February 1, 2023
Time Trends in Patient Characteristics of New Rivaroxaban Users with Atrial Fibrillation in Germany and the NetherlandsAnnemarie Voss, Elisabeth Smits, Karin M A Swart, et al.
Pageof 4